Back to News
Market Impact: 0.3
Corcept Reports Positive Phase 2 BELLA Results For Lifyorl In Platinum-Resistant Ovarian Cancer
Source: Nasdaq
Healthcare & Biotech
Corcept Therapeutics reported positive Part A results from its Phase 2 BELLA trial of Lifyoril (relacorilant) combined with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer. The provided article text contains no efficacy figures or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
CORT0.65
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers
- Genmab shares jump 13% on colorectal cancer drug trial results